Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

Cancer Gene Therapy

Volumn 9, Issue 7, 2002, Pages 567-572

  Buller, Richard E ^a   Shahin, Mark S ^a   Horowitz, Jo Ann ^b   Runnebaum, Ingo B ^c,d   Mahavni, Vikas ^a   Petrauskas, Stan ^b   Kreienberg, Rolf ^c,d   Karlan, Beth ^e   Slamon, Dennis ^e   Pegram, Mark ^e  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Gene therapy; Ovarian cancer survival; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; ALTRETAMINE; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PLATINUM; PROTEIN P53; SCH 58500; TOPOTECAN; UNCLASSIFIED DRUG;

ADENOVIRUS; AGED; ARTICLE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; TIME; TUMOR SUPPRESSOR GENE; ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; GENE REPLACEMENT THERAPY; OVARY CANCER; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TREATMENT FAILURE;

ADENOVIRIDAE; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; GENES, P53; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RECURRENCE; TIME FACTORS; HUMAN; MIDDLE AGE;

EID: 0036019372     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700473     Document Type: Article

References (27)

1. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
2. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
3. Phase II study of liposomal doxorubicin in advanced gynecologic cancers
4. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynecologic oncology group study
5. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer
6. Genetics and ovarian carcinoma
7. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
8. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
9. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
10. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
11. Distant metastases in ovarian cancer: Why do they occur?
12. Brain metastases in epithelial ovarian carcinoma
13. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma
14. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
15. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
16. Tamoxifen in platinum-refractory ovarian cancer: A gynecologic oncology group ancillary report
17. Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy
18. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
19. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy
20. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
21. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy
22. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
23. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
24. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma
25. Effective radiotherapeutic palliation after chemotherapy failure
26. Field cancerization: Why late "recurrent" ovarian cancer is not recurrent
27. Multidose intraperitoneal (IP) rad/p53 (SCH 58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival